Phase I Study of Nimotuzumab in Solid Tumours
A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours
Sponsor: CIMYM BioSciences
This PHASE1 trial investigates Advanced and/or Metastatic Solid Tumours and is currently completed. CIMYM BioSciences leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Jun 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CIMYM BioSciences
- YM BioSciences
For direct contact, visit the study record on ClinicalTrials.gov .